• Elena Fioravanzo

SOT 2021: my first week highlights

Even if I am missing the social aspect of the SOT Annual Meeting, I am enjoying the scientific content of the conference and the fact that all Scientific Sessions, Featured Sessions, poster presentations, and Exhibitor-Hosted Sessions also will be available on demand to meeting registrants through May 31, 2021, makes it easy to catch up.

Among the lectures I followed the first week, the one given by Alexander Amberg of Sanofi, "Development of In Silico Models from In Vivo Drug Toxicity Data and Their Successful Application for Regulatory Submission" in the "Industrial Applications of Artificial Intelligence in Toxicology" session was particularly interesting. Validation studies showed that with the approach presented, in silico models could be developed to predict toxicity findings in main target organs for the use in preclinical drug development. Additionally, these in silico models have been successfully applied for regulatory purposes with the approval of the qualification of non-genotoxic Cyamemazine impurities only based on results from in silico predictions with no additional in vivo toxicity data.

In the same session Andreas Bender, Cambridge University, presented "Toward Integrated Compound Safety Assessment, in Particular the Use of ’Omics Data and Pharmacokinetics Information, in Toxicity and Safety Prediction" an interesting description of how ‘-omics’ data (such as transcriptomics data and cellular morphology screening data) can be used for the understanding and prediction of compound safety, and outline what is needed for the further development of the field. For more details: http://www.drugdiscovery.net/2021/01/22/artificial-intelligence-in-drug-discovery-what-is-realistic-what-are-illusions-parts-1-and-2/

Another session I particularly enjoyed is "A Future Framework for Application of In Vitro Metabolism and QIVIVE Models to Inform Risk Assessment" where the application of in vitro metabolism and QIVIVE in various decision-making contexts was demonstrated through various case studies. An initial framework is outlined to learn how in vitro technologies can be used to increase confidence in chemical safety and inform risk assessment. The session begins with a brief review of recent technological advances. Each speaker then presents a novel case study illustrating the benefits and complexities of adopting in vitro metabolism and QIVIVE models for chemical risk assessment. In this context the Integrated Chemical Environment (ICE) with the 2020 updates to improve the In Vitro to In Vivo Extrapolation (IVIVE) tool is interesting. ICE now allows users to upload their own data for IVIVE analyses and it will become one of the tools that I routinely use.


Highlights of this week will be posted next Monday.